Trial of Tirzepatide for the Treatment of Cannabis Use Disorder (NCT07468552) | Clinical Trial Compass
Not Yet RecruitingPhase 2
Trial of Tirzepatide for the Treatment of Cannabis Use Disorder
100 participantsStarted 2026-11-15
Plain-language summary
The purpose of this randomized, double-blind, placebo-controlled, multi-site clinical trial is to evaluate the safety and efficacy of tirzepatide in a sample of 100 patients diagnosed with moderate or severe CUD by DSM-5 criteria.
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Between 18 and 70 years of age
* Meets DSM-5 criteria for moderate or severe CUD
* Interested in treatment for cannabis use disorder
* Able to understand the study procedures and written informed consent in English
* Willing to comply with all study procedures and medication instructions
* If female, is not pregnant, and agrees to use acceptable birth control methods
Exclusion Criteria:
* Body Mass Index (BMI) ≤ 23 kg/m²
* Presence of a medical or psychiatric disorder that contraindicates participation in the study
* Substance use disorder other than tobacco or mild alcohol-use disorder
* Known allergy or hypersensitivity to Tirzepatide, any GLP-1 or GIP receptor agonist, or any of the excipients in the product
* Current or recent (past 30 days) use of GLP-1 receptor agonists or other weight-loss drug
* Current or recent (past 6 months) enrollment in substance use disorder treatment
* Current or planned pregnancy and breastfeeding
* Living or medical situation that would interfere with adherence to the study protocol